Member Info for JohnHenry

Im not an owner of shares, however i like the company and its products have been a follower for years.

However my concern is the cash position which is dire imho youve only gotta read the RNS.

Bio, medtech companies are having a torrid time raising funds, look at DEST AGL POLX GDR RENE C4X and many more.

My last posts until funding

Possibly another curve ball if they cant get funding, will they take it private.

Deleno47 the Interims are hard facts. The cash position once again is dire you cant hide those facts.

How they get cash into the business ? Maybe a JV, maybe equity, maybe a bit of both. But what we do know is they need funds and fast.

Imho cash will be very low if they continue to burn at the present rate cash will be gone end of October

Substantial funding will be required by the Company to progress through Phase I clinical trials over the next two years. To the extent that the Company raises additional funds by issuing equity securities, the Company's shareholders may experience dilution. Any debt financing, if available, may involve restrictive covenants.

I suggest you all read the going concern statement

Stand out for me is the cash burn half the funds raised end of Feb gone in 4 months end of June.

3 Months on im guessing cash levels are pretty low. Going concern statement says it all.

Eureka01 i guess they are running the company on fresh air from mid 2025 to mid 2026

And there sit the issue Boom Boom the UK market.

The likes of Hobson etc aint gonna sit around being valued by the UK market which is basically F

Lets face it if there was very little helium they wouldn't have bothered with the expense of getting a geological model commissioned

Forget hope hype potential focus on cash, revenue, funding.

Im talking pre breakeven companies.

In case you hadn't noticed in this bear market Sectors is irrelevant its all about cash revenue and then growth.

Where have you been these past 4 years.

Just to get valuations out of the clouds

Silver bullet revenue booked for 2024 so far £8.4M cash flow positive £200K H1. valuation £8.4M

Like i said within a few years, US listing 2025 imho will delist from uk 2027

Revenue Revenue Revenue

Forget the recent spike on NICE news. Reality check, cold hard thanks Imho probably around £250k in revenue this financial year. Valuation £10M crazy

johnlay**** im not knocking the products absolutely first class.

im saying a reality as to the valuation of the company.

Investors recently have had a big reality check with GDR.

Sales /cash burn.

Ever notice why theres never any revenue targets put out to investors.

At least companies like POLX in a very similar position to GDR but with a vastly bigger market are upfront with targets and have said they will be profitable by the end of 2027 thats 3 years away.

POLX for example have an 18Months cash runway, a professional sales force, highly competent commercial CEO, revenue target of 3.5M already hit for 2024 and are valued at £17 M

Now even if GDR had achieved revenue of £3.5M for 2024 you wouldnt expect a valuation any higher than POLX

That would equate to just over 3p per share.

Now can you see how vastly overpriced GDR is

Eureka01 You need to look at the hard fact GDR are gonna need funding again next year but at what price.

GDR have moved on to commercialisation/Sales and will be valued accordingly its a far tougher valuation than when your R&D

3 X revenue is the norm.

Eureka01 BREAKEVEN what the F are you serious. £4.5M will last them 12 months. Do you honestly think Miele is gonna land £5M in sales in 12 months. AIHL has done £100,000 in the last 12 months.

Your on cloud cuckoo